Cost-effectiveness of interferon α or peginterferon α, with ribavirin for histologically mild chronic hepatitis C


Grieve, Richard, Roberts, Jennifer, Wright, Mark, Sweeting, Michael, DeAngelis, Daniela, Rosenberg, William, Bassendine, Margaret, Main, Janice and Thomas, Howard (2006) Cost-effectiveness of interferon α or peginterferon α, with ribavirin for histologically mild chronic hepatitis C. Gut, 55, (9), 1332-1338. (doi:10.1136/gut.2005.064774).

Download

Full text not available from this repository.

Original Publication URL: http://dx.doi.org/10.1136/gut.2005.064774

Description/Abstract


Background: For patients with mild chronic hepatitis C the cost-effectiveness of antiviral therapy is unknown.

Aims: To assess whether anti-viral therapy (either interferon α or peginterferon α combined with ribavirin) is cost-effective at a mild stage compared to waiting and only treating those cases whoprogress to moderate disease.

Patients: Cases with mild chronic hepatitis C.

Methods: A cost-effectiveness model estimates long-term costs and outcomes for patients with mild chronic hepatitis C. The model uses effectiveness and cost data from the UK mild hepatitis C RCT, combined with estimates of disease progression and cost from observational studies.

Results: Antiviral treatment at a mild rather than a moderate stage improved outcomes measured by Quality Adjusted Life Years (QALYs) gained. The mean cost per QALY gained from
antiviral treatment with interferon α−2b and ribavirin, compared to no treatment at a mild stage, was £4,535 ($7,108) for patients with genotype non-1 and £25,188 ($39,480) for patients with
genotype 1. Providing peginterferon α−2b and ribavirin at a mild rather than a moderate stage was also associated with a gain in QALYs; the costs per QALY gained were £7,821 ($12,259)
for patients with genotype non-1 and £28,409 ($44,528) for patients with genotype 1.

Conclusions: For patients with chronic hepatitis C, it is generally more cost-effective to provide antiviral treatment at a mild rather than a moderate disease stage. For older patients (aged 65 or over) with genotype 1, antiviral treatment at a mild stage is not cost-effective.

Item Type: Article
ISSNs: 0017-5749 (print)
Related URLs:
Keywords: cost-effectiveness model, cost analysis, antiviral therapy
Subjects: Q Science > QR Microbiology > QR355 Virology
R Medicine > RM Therapeutics. Pharmacology
R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
Divisions: University Structure - Pre August 2011 > School of Medicine > Infection, Inflammation and Repair
ePrint ID: 27074
Date Deposited: 25 Apr 2006
Last Modified: 27 Mar 2014 18:15
URI: http://eprints.soton.ac.uk/id/eprint/27074

Actions (login required)

View Item View Item